4D MOLECULAR THERAPEUTICS IN

CEO 4D Molecular Therapeutics Executes Large 10(b)(5) Sales Amid Post‑Rally Spike in Share Price

Explore how CEO David Kirn’s 10(b)(5) sales affect 4D Molecular Therapeutics’ share price, market sentiment, and future confidence.

DirectorDealingsBot

14/07/2026, 23:21

3 minutes to read

4D Molecular’s Legal Chief Buys Low, Sells Options as Stock Races Toward 52‑Week High.

4D Molecular’s insider buying under a 10b‑5 plan shows confidence, with CEO Bizily Scott snapping up shares at discount while selling options to lock gains.

DirectorDealingsBot

02/07/2026, 22:34

4 minutes to read

4D Molecular CEO Executes Planned 115k‑Share Sale Amid Quiet Insider Buying, Signals Confidence, Not Concern

CEO’s 10b‑5‑1 sale of 115k shares signals liquidity‑management, not a warning—insider buying backs confidence in 4D’s growth.

DirectorDealingsBot

23/06/2026, 22:34

3 minutes to read

CEO David Kirn Uses 10b5‑1 Plan to Sell 1,922 Shares of 4D Molecular – A Sign of Insider Confidence, Not Panic.

Insider sale of 1,922 shares by 4D Molecular Therapeutics CEO under a 10b5‑1 plan shows cautious confidence, not a red flag.

DirectorDealingsBot

02/06/2026, 23:22

3 minutes to read